Document is current

Article History

Received: 7 July 2022

Revised: 24 October 2022

Accepted: 24 October 2022

First Online: 21 November 2022

Declarations

:

: Noriko Fukuhara received research funding from Bayer, Celgene, Chugai, Genmab, Incyte Corporation; and advisor or consultant fees from AstraZeneca, AbbVie, Eli Lilly, Novartis, HUYA Bioscience; has received honoraria from AstraZeneca, BMS, Chugai, CSL Behring, Dainippon Sumitomo, Eisai, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ono, Ohtsuka, Sanofi, Symbio, Takeda, Zenyaku. Koji Kato is an advisor or consultant for AbbVie, AstraZeneca, Celgene, Chugai, Eisai, Janssen, and Novartis; has received honoraria from Celgene, Chugai, Janssen, Kyowa Kirin, Merck, Mundi, Novartis, Ono, Sumitomo Dainippon, Takeda; and reports research support from AbbVie, Celgene, Chugai, Eisai, Janssen, Kyowa Kirin, Ono, Novartis, Takeda. Hideki Gotohas received honoraria from Bristol-Myers Squibb, Eisai, Janssen, Chugai, Novartis, SymBio, Kyowa-Kirin, Astellas, MSD and Daiichi-Sankyo; and has received research grants from Bristol-Myers Squibb, SymBio and Kyowa-Kirin.. Tajima Takeshi, Mayu Kawaguchi, Kota Tokushige are employees of Novartis Pharma K.K. Koichi Akashi received research funding from AbbVie, Asahi Kasei, Astellas Pharma, Chugai, Daiichi Sankyo, Eisai, Kyowa Kirin, Mochida, MSD, Mundipharma, Nihon Shinyaku, Ono, Ostuka, Sanofi, Shin Nippon Biomedical laboratories, Shionogi, Sumitomo Dainippon, Taiho, Takeda, Toyama, Yakult; and consultant fees from AbbVie, Astellas Pharma, BMS, Celgene, Chugai, Eisai, Janssen, Kyowa Kirin, Novartis. Takanori Teshima is an advisor or consultant for Merck, Novartis, Takeda; has received honoraria from Bristol-Myers Squibb, Fuji Pharma, Kyowa Kirin, Merck, Nippon Shinyaku, Pfizer, Takeda, Teijin Pharma; reports research support from Astellas, Chugai Pharma, Kyowa Kirin, Novartis, Sanofi; reports grants from the Japan Society for the Promotion of Science and Japan Science and Technology Agency; and has received assistance with manuscript preparation for Janssen, Novartis. Hideo Harigae has received honoraria from BMS, Novartis, Chugai, Janssen; and reports research support from Astellas. Schuster J Stephen is an advisor or consultant for Acerta, AlloGene, AstraZeneca, BeiGene, Celgene/Juno, Genentech/Roche, Loxo Oncology, Novartis, Tessa Therapeutics; has received honoraria from Acerta, AlloGene, AstraZeneca, BeiGene, Celgene, Genentech/Roche, Loxo Oncology, Novartis, Nordic Nanovector, Pfizer, Tessa Therapeutics; has participated in steering committees for AbbVie, Celgene, Novartis, Juno, Nordic Nanovector, Pfizer; reports research support from AbbVie, Acerta, Celgene/Juno, DTRM Bio, Genentech, Incyte, Merck, Novartis, Portola, TG therapeutics; and holds a patent with Novartis. Catherine Thieblemont has received honoraria from Celgene, AbbVie, Bayer, Janssen, Roche, Incyte, Novartis, Gilead; reports research funding from Roche; and travel support from Roche, Janssen-Cilag, Kite/Gilead, Novartis. Martin Dreyling is a scientific advisory board member for Astra Zeneca, Beigene, BMS/Celgene, Genmab, Gilead/Kite, Incyte, Janssen, Lilly/Loxo, Morphosys, Novartis, Roche; received honoraria from Amgen, Astra Zeneca, BMS/Celgene, Gilead/Kite, Incyte, Janssen, Novartis, Roche; reports research support from Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche. Nathan Fowler is an advisor or consultant for Roche/Genentech, TG Therapeutics, Verastem, Bayer, Celgene, Novartis; and reports research support from Roche, Celgene, Gilead Sciences, TG Therapeutics, Novartis, AbbVie, BeiGene.